Unknown

Dataset Information

0

Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.


ABSTRACT: Objective:To investigate the association between using febuxostat and cardiovascular events. Methods:Systematic search of randomized controlled trials was performed using PubMed/MEDLINE, Cochrane review, and EMBASE databases through April 17, 2019. Meta-analysis was performed using random effect model and estimates were reported as risk difference (RD) with 95% CIs. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. The main outcomes of interest were cardiovascular mortality and all-cause mortality. Results:A total of 15 randomized controlled trials (16,070 participants) were included. The mean ± SD age was 58.1±11.7 years. At the median follow-up of 6.4 months, use of febuxostat was not associated with statistically significant risk of cardiovascular mortality (RD, 0.12%; 95% CI, -0.25% to 0.49%; I 2 =48%; low certainty evidence), all-cause mortality (RD, 0.20%; 95% CI, -0.28% to 0.68%; I 2  =60%; very low certainty evidence), major adverse cardiovascular events (RD, 0.40%; 95% CI, -0.34% to 1.13%; I 2 =26%; low certainty evidence), myocardial infarction (RD, -0.06%; 95% CI, -0.29% to 0.17%; I 2  =0%; moderate certainty evidence), stroke (RD, 0.10%; 95% CI, -0.15% to 0.35%; I 2 =0%; moderate certainty evidence), or new-onset hypertension (RD, 1.58%; 95% CI, -0.63% to 3.78%; I 2 =58%; very low certainty evidence). These findings were consistent in patients with existing cardiovascular disease. Conclusion:This meta-analysis suggested that use of febuxostat was not associated with higher risk of mortality or adverse cardiovascular outcomes in patients with gout and hyperuricemia. The results were limited by low to moderate certainty of evidence.

SUBMITTER: Al-Abdouh A 

PROVIDER: S-EPMC7411164 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Al-Abdouh Ahmad A   Khan Safi U SU   Barbarawi Mahmoud M   Upadhrasta Sireesha S   Munira Srajum S   Bizanti Anas A   Elias Hadi H   Jat Asadulla A   Zhao Di D   Michos Erin D ED  

Mayo Clinic proceedings. Innovations, quality & outcomes 20200805 4


<h4>Objective</h4>To investigate the association between using febuxostat and cardiovascular events.<h4>Methods</h4>Systematic search of randomized controlled trials was performed using PubMed/MEDLINE, Cochrane review, and EMBASE databases through April 17, 2019. Meta-analysis was performed using random effect model and estimates were reported as risk difference (RD) with 95% CIs. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation a  ...[more]

Similar Datasets

| S-EPMC10535365 | biostudies-literature
| S-EPMC7727482 | biostudies-literature
| S-EPMC3648543 | biostudies-literature
| S-EPMC3577664 | biostudies-literature
| S-EPMC8327383 | biostudies-literature
| S-EPMC4802486 | biostudies-literature
| S-EPMC4943241 | biostudies-literature
| S-EPMC5324238 | biostudies-literature
| S-EPMC3507563 | biostudies-other
| S-EPMC4950703 | biostudies-other